Lupin receives FDA approval for generic Seroquel XR tabs

The drug is indicated for the treatment of schizophrenia

Lupin has received final approval for its Quetiapine Fumarate extended-release tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg from the USFDA to market a generic version of AstraZeneca Pharmaceuticals LP’s Seroquel XR tablets 50 mg, 150 mg, 200 mg, 300 mg and 400 mg.

Lupin’s Quetiapine Fumarate extended-release tablet is indicated for the treatment of schizophrenia; acute manic or mixed episodes in bipolar I disorder alone or as an adjunct to lithium or divalproex; acute depressive episodes in bipolar disorder; maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex and as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.